Forum Ventures

Forum Ventures is a different kind of investor, and founders should understand the difference before pitching. Headquartered in New York with operations across the United States and Canada, Forum is a pre-seed accelerator and venture studio focused on B2B SaaS, with healthcare IT and AI/ML in healthcare among its active verticals. Check sizes run under $250K, which positions Forum at the absolute earliest stage of institutional capital, often before founders have raised any other money. The firm runs a structured accelerator program alongside its venture studio activity and writes follow-on checks selectively into program graduates and other early-stage B2B SaaS companies. For digital health founders building B2B software, Forum is a credible early-stage option; for any other healthcare profile, the firm is not a fit.

The stated focus is B2B SaaS at pre-seed, with healthcare IT and AI/ML in healthcare carved out as priority verticals. The implied target company is a one to three person team building B2B software for healthcare buyers, often without revenue and frequently still validating product-market fit. Forum’s accelerator structure means it offers more than capital: portfolio companies receive structured programming on go-to-market, fundraising preparation, and operating discipline. The firm explicitly markets to underrepresented founders, and the program cohorts reflect that emphasis. The implication for founders is that Forum’s value proposition is heaviest at the very beginning of a company’s life and tapers as the company moves into seed and Series A; founders who already have meaningful traction may find that Forum’s program structure is less relevant.

The firm’s broader B2B SaaS portfolio across verticals is large, with hundreds of companies passing through the accelerator. In healthcare specifically, founders should review the Forum Ventures portfolio page directly to identify recent healthcare IT and AI/ML investments. The pattern in B2B healthcare SaaS at pre-seed favors companies attacking provider workflow inefficiencies, payer operations, employer benefits administration, and clinical operations rather than regulated medical software requiring FDA clearance. Forum’s check size and stage profile mean it is unlikely to back companies requiring significant clinical evidence generation before commercial launch.

Check size under $250K means Forum is rarely the lead in a priced round; the firm typically participates as a SAFE investor at pre-seed or as the primary capital source for accelerator program participants. Co-investment patterns include other pre-seed funds, angels, and selected seed funds that bridge into the firm’s deal flow. Forum has historically supported program graduates with introductions to seed-stage co-investors, which is one of the firm’s most concrete value-adds. Founders should evaluate Forum partly on the strength of its downstream investor relationships, since the firm’s primary role is to position companies for the next institutional round rather than to fund them through it.

The team operates across investing, program management, and venture studio functions. Founders should research the current partner roster via the firm’s website and target the partner or program lead with the most relevant sub-vertical experience. Decision-making for the accelerator runs through structured selection processes with cohort timing, while one-off investments outside the program follow a more typical venture process. Cold applications to the accelerator are an explicit part of the model, which differentiates Forum from most institutional firms.

Warm intros help but are less critical than at higher-stage firms. The accelerator application process is publicly accessible, which gives unconnected founders a real entry path. Forum’s team is reasonably active publicly, with podcast appearances on early-stage founder shows and frequent presence at pre-seed and accelerator-focused events. Founders should pay particular attention to the firm’s writing on B2B SaaS pre-seed strategy, which provides clear signal on what the team is looking for in pitches. Cohort kickoffs and demo days are the most visible public moments and are useful for benchmarking the kinds of companies Forum backs at the moment of investment.

Approach Forum when you are at pre-seed stage, building B2B SaaS for healthcare buyers, and ready for a structured accelerator program or a small first institutional check. Do not approach for therapeutics, devices, clinical services, consumer health products, or any healthcare company already past the seed stage. Among portfolio founders, the firm has a reputation for genuine program engagement, candid feedback, and a willingness to back founders before traditional institutional firms will look. The trade-off is structural: Forum is a stepping stone, not a long-term board partner. Founders should think of the firm as a launch partner whose value is concentrated in the first twelve months and plan their syndicate accordingly.